Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

MediLink Therapeutics (Suzhou) Co: Clinical Trials & FDA Approval Profile

MediLink Therapeutics (Suzhou) Co (Global / Institutional) sponsors 19 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 19 active protocols (15 recruiting now), 0 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)Not reported

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for MediLink Therapeutics (Suzhou) Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)19
Active Pipeline (Recruiting Now)19 (15)
Completed vs Stopped Early0 / 0 (0.0%)
Median Closed Actual EnrollmentNot reported
Physical Hospital Site Disclosure61.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With MediLink Therapeutics (Suzhou) Co
Hospital Research SiteLocationShared Protocols
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong9
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality5
Harbin Medical University Cancer HospitalHarbin, Heilongjiang4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by MediLink Therapeutics (Suzhou) Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06107686A Study of YL202 in Selected Patients With Advanced Solid TumorsPhase IIRECRUITING
NCT06241846A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPCPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the MediLink Therapeutics (Suzhou) Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI